Go to Health Care Provider version
| Diagnosis | Neuroblastoma | Study Status | Open |
| Phase | II |
| Age | Child, Adult - (up to 31 years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Etoposide: oral
DFMO: oral |
| Last Posted Update | 2024-03-19 |
| ClinicalTrials.gov # | NCT04301843 |
International Sponsor
Giselle ShollerPrincipal Investigators for Canadian Sites
Montreal Children's Hospital – Dr. Sharon Abish
CancerCare Manitoba – Dr. Ashley Chopek
CHU Ste-Justine – Dr. Pierre Teira
Alberta Children's Hospital – Dr. Melanie Finkbeiner
CHU de Quebec - Dr. Bruno Michon
Janeway Hospital – Dr. Paul MooreheadCentres
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Medical contact
Dr. Victor Lewis
Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Raoul Santiago
Social worker/patient navigator contact
Isabelle Audet
Clinical research contact
Barbara Desbiens
Study Description
This study is to assess the effectiveness of a drug called Difluoromethylornithine (DFMO) in combination with etoposide for patients with neuroblastoma that has come back, or is not responidng to current treatment. DFMO is a medication taken by mouth. It is an blocker of ornithine decarboxylase, an enzyme involved with polyamine biosynthesis in the cancer cells, including neuroblastoma cells.
Inclusion Criteria
- Patients less than 31 years of age
- Diagnosis of neuroblastoma that has come back or is not responding to treatment
- Patients can have active or no active disease at the time of study start
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.
